APA (7th ed.) Citation

YC, H., MC, W., CH, C., YT, L., CI, L., HC, C., . . . MT, W. (2026). The addition of celecoxib enhances the therapeutic benefit of cabozantinib and anti-PD1 in hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 196, 119102. https://doi.org/10.1016/j.biopha.2026.119102

Chicago Style (17th ed.) Citation

YC, Hsu, et al. "The Addition of Celecoxib Enhances the Therapeutic Benefit of Cabozantinib and Anti-PD1 in Hepatocellular Carcinoma." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 196 (2026): 119102. https://doi.org/10.1016/j.biopha.2026.119102.

MLA (9th ed.) Citation

YC, Hsu, et al. "The Addition of Celecoxib Enhances the Therapeutic Benefit of Cabozantinib and Anti-PD1 in Hepatocellular Carcinoma." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 196, 2026, p. 119102, https://doi.org/10.1016/j.biopha.2026.119102.